A Study of the Continuation Rate of Glaucoma Eye Drop Medication by Combination Medication

A Study of the Continuation Rate of Glaucoma Eye Drop Medication by Combination Medication (Longitudinal Study Using Medical Fee Detailed Data) - A Study of the Continuation Rate of Glaucoma Eye Drop Medication by Combination Medication (Longitudinal Study Using Medical Fee Detailed Data)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056449

Enrollment

66206

Registered

2024-12-19

Start date

2025-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed with glaucoma or ocular hypertension (ICD10 code H40. Excluding glaucoma included in H402, H405: "Angiogenic glaucoma" and H400: "Primary angle-closure glaucoma") during the inclusion period and started concomitant therapy with the target drug (monotherapy for some secondary outcomes) in the same month Patients who are 18 years of age or older as of the index date

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Continuation rate of glaucoma eye drops in glaucoma patients	—

Secondary

Measure	Time frame
Continuation rate of monotherapy with glaucoma eye drops in glaucoma patients	—

Countries

Japan

Contacts

Public ContactRikiya Toda

Otsuka Pharmaceutical Co., Ltd. Medical Affairs

Toda.Rikiya.a@otsuka.jp06-6943-7722

Outcome results